Beyond Minoxidil: Off-Label Therapies for Male Androgenetic Alopecia—A Systematic Review with Network Meta-Analyses

This study critically reviewed recent evidence (2020–2025) on treatments like platelet-rich plasma, photobiomodulation, stem cells, and exosomes for androgenetic alopecia, finding emerging but limited efficacy data and emphasizing the need for standardized protocols to enhance transparency and patient safety.

This randomized trial found that topical GT20029 significantly increased hair counts and width in Chinese men with androgenetic alopecia over 12 weeks, showing better results than placebo, with the 0.5% once daily and 1.0% twice weekly doses particularly effective.

This study found that while exosome therapy shows promise for treating AGA, AA, and CIA, its integration into routine practice will depend on rigorous clinical trials and standardized manufacturing and regulatory practices to ensure safety and reproducibility.

The study did not find evidence to support using botulinum toxin as a treatment for androgenetic alopecia.

This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.

This study found that an exosome formulation with plant extracts significantly increased hair regrowth in men with male pattern alopecia compared to a placebo, without notable adverse effects.

In this study, a novel compound named AH-001 demonstrated effective androgen receptor protein degradation, reducing hair loss progression in a mouse model of androgenetic alopecia, with minimal systemic exposure and side effects, suggesting potential for safer treatment.

Botulinum toxin may help treat male pattern baldness.

IVL3001 is safe, effective, and better than oral finasteride for treating hair loss.

In this study, a combination of 5% minoxidil lotion and 0.25% topical finasteride spray significantly increased hair density and improved photographic assessments in men with androgenetic alopecia compared to the treatments used alone, with all methods showing good tolerability.

This review discusses botulinum toxin A as a treatment for various types of hair loss and reports no clinical results; the authors emphasize the need for comprehensive evaluations and further research.

This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.

This study found that watercress extract may help treat hair loss by increasing RSPO1 secretion and decreasing DKK1 secretion, improving hair thickness and density in clinical trials.

This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.

This study reported that while topical minoxidil exhibits hair regrowth in androgenetic alopecia, oral minoxidil 5 mg/day was more effective than topical forms after six months, with low doses also potentially effective for women and other hair loss types.

This study found that while both cetirizine 1% and minoxidil 5% increased hair density in men with androgenetic alopecia, minoxidil showed a significantly higher improvement, and both treatments lost effectiveness after 8 weeks without use; cetirizine was well-tolerated with no significant adverse reactions.

This review highlights various alternative and complementary treatments for androgenic alopecia, noting that while only two FDA-approved options exist, increased awareness among dermatologists of supportive evidence for other therapies may better inform patient education.

This study suggests platelet-rich plasma may be more effective than other non-surgical treatments for male androgenetic alopecia, while low-level laser therapy ranks highest for women; however, the evidence quality was low.

This study found that platelet-rich plasma combined with topical minoxidil was more effective in increasing hair density for male-type baldness than either treatment alone.

This study found that a marine complex supplement significantly reduced hair shedding and increased hair growth in men with thinning hair over 180 days.

This study found that topical application of Serenoa repens extract increased hair count in men with androgenetic alopecia, suggesting it could be an alternative for those unable to use standard medications.

This pilot study found that a multimodal minoxidil microemulsion with diclofenac and tea tree oil was more effective and safer than minoxidil alone for treating androgenic alopecia over 32 weeks.

In this study, 68% of patients treated with finasteride showed improved hair growth in male androgenetic alopecia, compared to 38% with Serenoa repens, indicating finasteride's superior efficacy.

This study found that topical melatonin solution was associated with positive effects on hair density and reduction in hair loss for androgenetic alopecia, with good tolerability reported in several clinical trials.

This study found that procyanidin oligomers from apples and barley may stimulate hair growth by promoting hair epithelial cell proliferation and protecting them from apoptosis via MEK activation in a murine model.

This study found that 0.7% apple procyanidin oligomers applied externally for six months significantly increased hair growth in men with male pattern baldness compared to placebo, with no observed adverse effects.

This study found that 60% of men with mild to moderate androgenetic alopecia showed improvement after treatment with botanically derived 5AR inhibitors, suggesting these compounds may be effective, though larger trials are needed.

In this study, 1% procyanidin B-2 tonic significantly increased the number of total and terminal hairs on the scalp of male participants compared to a placebo after 6 months of use.

In this study, topical 2% minoxidil did not significantly improve hair density measures in men with male pattern baldness, although there was no deterioration, suggesting a potential prophylactic effect.

This study found that 2% minoxidil solution was about three times more effective than a placebo in improving hair growth in men with early male pattern alopecia over 24 weeks.

In this study, 2% minoxidil solution was found to be a safe and more effective treatment for early male pattern baldness compared to placebo.

In this study, topically applied 2% minoxidil solution was found to be more effective than placebo for promoting hair regrowth in men with early male pattern baldness over 24 weeks.

Lowest effective minoxidil concentration is 1%, but 2% works better for male pattern baldness.